NIPH Clinical Trials Search

Basic Information

Recruitment status	recruiting
Health condition(s) or Problem(s) studied	Type 2 Diabetes Mellitus
Date of first enrollment	05/12/2011
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : LY2189265 INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : LY2189265 0.75 mg administered by subcutaneous injection once weekly for 52 weeks

Outcome(s)

Primary Outcome
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	Not applicable
Age maximum	Not applicable
Gender	Both
Include criteria	Patients who have had a diagnosis of type 2 diabetes mellitus before screening Patients who have been taking SU (Glibenclamide, Gliclazide, Glimepiride), biguanides, TZD, a-GI or glinides monotherapy for at least 3 months before screening and have been on a stable dose for at least 8 weeks before screening Patients must have a qualifying HbA1c value of 7.0% to 11.0% at screening Patients who have a body mass index (BMI) of 18.5 kg/m2 to 35.0 kg/m2
Exclude criteria